Image de couverture de livre

Partial Residual Plots as an Integrated Model Diagnostic Tool in Model‐Based Meta‐Analysis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	John Maringwa, Paul Matthias Diderichsen, Chandni Valiathan
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation
par: Wangda Zhou, et autres
Publié: (2025)

Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer
par: Abhishek G. Sathe, et autres
Publié: (2024)

Application and Quality of Model‐Based Meta‐Analysis in Pharmaceutical Research: A Systematic Cross‐Sectional Analysis and Practical Considerations
par: Zhirong Yang, et autres
Publié: (2024)

A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition
par: Sheetal K. Panday, et autres
Publié: (2025)

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP
par: Munjal Patel, et autres
Publié: (2025)

Corrigendum: “Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model‐Based Meta‐Analysis of American College of Rheumatology Response Criteria”
Publié: (2024)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
par: Jatinder Kaur Mukker, et autres
Publié: (2025)

Reply to “Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective”
par: Zhihua Li, et autres
Publié: (2025)

Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen
par: Peter N. Morcos, et autres
Publié: (2024)

Pharmacotherapy to Improve Cognitive Functioning After Acquired Brain Injury: A Meta‐Analysis and Meta‐Regression
par: Ruud van der Veen, et autres
Publié: (2024)

Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare Diseases
par: Susana Neves‐Zaph, et autres
Publié: (2024)

Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective
par: Celine M. Laffont, et autres
Publié: (2025)

The Framework of Precision Pharmacotherapy in Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis
par: Yuanming Chen, et autres
Publié: (2026)

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
par: Fan Huang, et autres
Publié: (2024)

QTc Interval Changes in Preeclampsia vs. Normal Pregnancy: A Systematic Review and Meta‐Analysis
par: Omar A. Aboshady, et autres
Publié: (2025)

Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models
par: Eunjin Hong, et autres
Publié: (2025)

Model‐Based Prediction of Clinically Relevant Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation
par: Katharina M. Götz, et autres
Publié: (2025)

Correction to “Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing”
Publié: (2025)

Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
par: Hongmei Duan, et autres
Publié: (2025)

Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome
par: Fei Tang, et autres
Publié: (2024)

Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes
par: Anik Chaturbedi, et autres
Publié: (2025)

Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis
par: Pooneh Soltantabar, et autres
Publié: (2024)

In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect‐Compartment Model—Commentary on Sheiner et al.
par: Mats O. Karlsson
Publié: (2025)

Reinforcement Learning and PK‐PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma
par: Alessandro De Carlo, et autres
Publié: (2024)

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form
par: Vivek Purohit, et autres
Publié: (2024)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
par: Tania Payo‐Serafín, et autres
Publié: (2024)

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
par: Million A. Tegenge, et autres
Publié: (2025)

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
par: Emily Mannix, et autres
Publié: (2026)

The Type of Follicle‐Stimulating Hormone Medication Given for In Vitro Fertilization Impacts Oocyte Retrieval: A Systematic Review and Meta‐Analysis
par: Toni J.F. Michael, et autres
Publié: (2025)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
par: Cornelius Cilliers, et autres
Publié: (2024)

Emerging Tools and Technologies for Microbiome‐Aware Drug Development
par: Henry J. Haiser, et autres
Publié: (2025)

Model‐Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC : A QSP Model for Alpelisib and Tipifarnib Combination
par: Jaehee Shim, et autres
Publié: (2026)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
par: Weihua Jiang, et autres
Publié: (2025)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
par: Yoo Jin Jang, et autres
Publié: (2024)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
par: Kunal S. Taskar, et autres
Publié: (2025)

Pathway‐Based Similarity Measurement to Quantify Transcriptomics Similarity Between Human Tissues and Preclinical Models
par: Paarth Parekh, et autres
Publié: (2024)

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
par: Annie Lumen, et autres
Publié: (2024)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
par: Sejung Hwang, et autres
Publié: (2024)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
par: Peiying Zuo, et autres
Publié: (2024)

Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”
par: Polly Paul, et autres
Publié: (2025)